Nonalcoholic fatty liver disease

Elizabeth M. Brunt(Washington University in St. Louis), Mary E. Rinella(University of Chicago)

Nature Reviews Disease Primers

December 16, 2015

10.1038/nrdp.2015.80

Cited by 832

Related Papers

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

|New England Journal of Medicine|2010|3.3k

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

|Hepatology|2023|2.9k

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

|Journal of Hepatology|2023|2.7k

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

|The Lancet|2014|2.2k

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

|The Lancet|2019|1.2k